LEADS BioLabs is a clinical-stage biotechnology company focused on the discovery, development, and commercialization of innovative therapies to address unmet medical needs in oncology, autoimmune diseases, and other significant health conditions. The company boasts a robust research pipeline that includes multiple novel antibody projects targeting tumor immunity and autoimmune disorders. Their research and development efforts are centered on creating therapies with proprietary intellectual property, particularly in the realm of antibody drug development. Notably, LEADS BioLabs has developed a range of dual-targeting bispecific antibodies, which are designed to enhance T-cell activation and improve therapeutic efficacy while minimizing systemic toxicity.

Among their key products, LBL-024 is a bispecific antibody targeting PD-L1 and 4-1BB, which aims to overcome immune suppression and enhance T-cell activation for cancer treatment. Other notable candidates include LBL-034, which targets GPRC5D and CD3 for multiple myeloma, and LBL-033, designed for gynecological cancers by targeting MUC16 and CD3. Additionally, LBL-007, a monoclonal antibody targeting LAG-3, has shown promising results in enhancing immune responses across various cancer types. The company is actively pursuing clinical trials and regulatory approvals for these innovative therapies, demonstrating its commitment to advancing cancer treatment and improving patient outcomes.

China

Leads Biolabs Nanjing Leads Biolabs Co., Ltd is a clinical-stage biotechnology company. Since 2014, the company has been operating in the development of single-target antibodies and bispecific antibody new drugs. It has also announced worldwide license and collaboration agreements for anti-LAG-3 antibody and received FDA approval for IND application for bispecific antibody. Leads Biolabs is also involved in the development and manufacturing of mAb candidates in collaboration with Chime Biologics and BeiGene.

LEADS BioLabs

Company Details